Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner - Endpoints News
8/3/2022 12:00:00 AM2 years 9 months ago
by John Carroll, Aayushi Pratap
by John Carroll, Aayushi Pratap
Roche has taken its next big step into the allogeneic CAR-T field, this time tying up alongside Poseida Therapeutics $PSTX with $220 million in upfront and quick cash in a trademark oncology alliance that comes with a mother lode of milestones. The deal — whi…
Alnylam $ALNY has laid claim to a major success in Phase III, with its RNAi drug patisiran hitting the primary endpoint in its APOLLO-B study for ATTR amyloidosis with cardiomyopathy, one of the most… [+798 chars]
full article...